Unusual cutaneous adverse effect of carbamazepine: A case of drug-induced vitiligo

Vitiligo is a chronic autoimmune skin disorder with a global prevalence of 0.5–2%, highest noted in the Indian subcontinent. Drug-induced vitiligo from carbamazepine is rare, with only two reported cases. This report describes a South Indian woman in her mid-30s who developed acrofacial vitiligo after 2 years of carbamazepine use. A dermatologist’s opinion was obtained and suggested carbamazepine withdrawal. Repigmentation occurred after 3 months of carbamazepine withdrawal, and a Naranjo score of 7 indicated a probable causal link. Clinicians should monitor long-term carbamazepine users for dermatological adverse effects, as early detection and discontinuation may reverse symptoms.